FIELD: medicine.
SUBSTANCE: invention concerns application of c-Abl-, PDGF-R-or c-kit-tyrosine kinase 4-(4-methylpiperazine-1-ilmethyl)-N-[4-methyl-3-(4-pyri-dyn-3-il)pyrimidine-2-ilamino) phenyl]-benzamide inhibitor or its pharmaceutically comprehensible salts for reception of a medical product for the prevention or treatment of diabetes (versions), for example, I type diabetes, II type diabetes and to packing of the given substance for administration to the patients with diabetes.
EFFECT: new property of the bond to prevent destruction of pancreas beta cells producing insulin in vitro and in vivo is shown.
8 cl, 3 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIONS OF THERAPEUTIC AGENTS APPLICABLE FOR TREATING CANCER | 2007 |
|
RU2447891C2 |
| COMBINATIONS OF THERAPEUTIC AGENTS FOR CANCER TREATMENT | 2007 |
|
RU2449788C2 |
| COMBINATIONS CONTAININS Bcr-Abl/c-Kit/PDGF-RTK INHIBITORS FOR TREATING CANCER | 2007 |
|
RU2452492C2 |
| TREATING TUBEROUS SCLEROSIS | 2007 |
|
RU2473343C2 |
| TREATING NEUROENDOCRINE TUMOURS | 2006 |
|
RU2487711C2 |
| KINASE INACTIVATORS AND METHODS OF THEIR APPLICATION | 2007 |
|
RU2442777C2 |
| COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2383545C2 |
| COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS | 2006 |
|
RU2411242C2 |
| NEW APPLICATION OF LIVER X RECEPTOR AGONISTS | 2006 |
|
RU2417078C2 |
| COMBINED THERAPY BY USING ANTIANGIOGENIC AGENTS AND TNF-ALPHA | 2002 |
|
RU2316337C2 |
